15 Set-It-and-Forget-It Stocks to Buy in 2026
Long-term wealth building requires choosing investments that could withstand various economic conditions.
Exelixis Inc. (EXEL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 15,709,500 | $688,547,385 | -20% | 3.25% |
| 2. | Renaissance Technologies Jim Simons | 13,914,043 | $609,852,505 | -10% | 0.95% |
| 3. | AQR Capital Management Cliff Asness | 13,658,388 | $598,647,141 | +49% | 0.31% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 5,277,258 | $231,302,218 | +1% | 0.14% |
| 5. | D E Shaw D. E. Shaw | 1,860,005 | $81,524,020 | +726% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.12 | 27,532 | $1,187,234.90 | 1,553,262 | 2025-11-25 | Filing | |
| $20.76 | 225,000 | $4,670,055.00 | 1,525,730 | 2024-05-30 | Filing | |
| $20.32 | 200,000 | $4,063,900.00 | 1,300,730 | 2024-05-28 | Filing | |
| $20.70 | 190,000 | $3,932,734.00 | 1,100,730 | 2024-02-21 | Filing | |
| $21.61 | 120,409 | $2,602,038.49 | 910,730 | 2023-11-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.50 | 47,918 | $2,132,351.00 | 616,106 | 2026-02-24 | Filing | |
| $44.35 | 29,873 | $1,324,867.55 | 664,024 | 2026-02-19 | Filing | |
| $44.01 | 99,574 | $4,382,251.74 | 279,942 | 2026-02-18 | Filing | |
| $44.30 | 20,030 | $887,329.00 | 20,590 | 2026-02-18 | Filing | |
| $44.50 | 44,087 | $1,961,871.50 | 20,590 | 2026-02-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 507 | $21,745 | 0.01% | |
| 2. | 0 | $0 | 0% |
News See All
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call. My name is Towanda, and I will be your operator for today.
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In
Exelixis, Inc. (NASDAQ:EXEL) is one of the best healthcare stocks under $50 to invest in. On February 4, Barclays revised the price target on Exelixis, Inc.
12 Best Healthcare Stocks Under $50 to Invest In
On January 27, Jared Holz, healthcare equity strategist at Mizuho, appeared on CNBC’s 'Power Lunch' to talk about healthcare stocks and the new proposals around Medicare Advantage.
Exelixis, Inc. (EXEL) Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch
TheFly reported on January 8 that H.C.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.
Exelixis, Inc. (EXEL): A Bull Case Theory
We came across a bullish thesis on Exelixis, Inc. on Business Invest’s Substack by Francesco Ferrari. In this article, we will summarize the bulls’ thesis on EXEL.
Exelixis, Inc. (NASDAQ:EXEL) Q3 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis' Third Quarter 2025 Financial Results Conference Call. My name is Sherry, and I'll be your operator for today.
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) got upgraded to Outperform from Market Perform by Leerink Partners.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Hedge Fund Resource Center